Merck Wants Fed. Circ. Redo On Decision Backing Axed IP
German drugmaker Merck has asked the Federal Circuit to rethink its decision upholding the invalidation of claims in two patents on the blockbuster multiple sclerosis drug Mavenclad, saying the ruling creates...To view the full article, register now.
Already a subscriber? Click here to view full article